• Something wrong with this record ?

3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo

N. Dayal, E. Řezníčková, DE. Hernandez, M. Peřina, S. Torregrosa-Allen, BD. Elzey, J. Škerlová, H. Ajani, S. Djukic, V. Vojáčková, M. Lepšík, P. Řezáčová, V. Kryštof, R. Jorda, HO. Sintim

. 2021 ; 64 (15) : 10981-10996. [pub] 20210721

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.

Persistent link   https://www.medvik.cz/link/bmc23004977

The 3H-pyrazolo[4,3-f]quinoline moiety has been recently shown to be a privileged kinase inhibitor core with potent activities against acute myeloid leukemia (AML) cell lines in vitro. Herein, various 3H-pyrazolo[4,3-f]quinoline-containing compounds were rapidly assembled via the Doebner-Povarov multicomponent reaction from the readily available 5-aminoindazole, ketones, and heteroaromatic aldehydes in good yields. The most active compounds potently inhibit the recombinant FLT3 kinase and its mutant forms with nanomolar IC50 values. Docking studies with the FLT3 kinase showed a type I binding mode, where the 3H-pyrazolo group interacts with Cys694 in the hinge region. The compounds blocked the proliferation of AML cell lines harboring oncogenic FLT3-ITD mutations with remarkable IC50 values, which were comparable to the approved FLT3 inhibitor quizartinib. The compounds also inhibited the growth of leukemia in a mouse-disseminated AML model, and hence, the novel 3H-pyrazolo[4,3-f]quinoline-containing kinase inhibitors are potential lead compounds to develop into anticancer agents, especially for kinase-driven cancers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004977
003      
CZ-PrNML
005      
20230425171829.0
007      
ta
008      
230418s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.1c00330 $2 doi
035    __
$a (PubMed)34288692
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Dayal, Neetu $u Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States
245    10
$a 3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo / $c N. Dayal, E. Řezníčková, DE. Hernandez, M. Peřina, S. Torregrosa-Allen, BD. Elzey, J. Škerlová, H. Ajani, S. Djukic, V. Vojáčková, M. Lepšík, P. Řezáčová, V. Kryštof, R. Jorda, HO. Sintim
520    9_
$a The 3H-pyrazolo[4,3-f]quinoline moiety has been recently shown to be a privileged kinase inhibitor core with potent activities against acute myeloid leukemia (AML) cell lines in vitro. Herein, various 3H-pyrazolo[4,3-f]quinoline-containing compounds were rapidly assembled via the Doebner-Povarov multicomponent reaction from the readily available 5-aminoindazole, ketones, and heteroaromatic aldehydes in good yields. The most active compounds potently inhibit the recombinant FLT3 kinase and its mutant forms with nanomolar IC50 values. Docking studies with the FLT3 kinase showed a type I binding mode, where the 3H-pyrazolo group interacts with Cys694 in the hinge region. The compounds blocked the proliferation of AML cell lines harboring oncogenic FLT3-ITD mutations with remarkable IC50 values, which were comparable to the approved FLT3 inhibitor quizartinib. The compounds also inhibited the growth of leukemia in a mouse-disseminated AML model, and hence, the novel 3H-pyrazolo[4,3-f]quinoline-containing kinase inhibitors are potential lead compounds to develop into anticancer agents, especially for kinase-driven cancers.
650    _2
$a protinádorové látky $x chemická syntéza $x chemie $x farmakologie $7 D000970
650    _2
$a proliferace buněk $x účinky léků $7 D049109
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a lidé $7 D006801
650    _2
$a akutní myeloidní leukemie $x farmakoterapie $x metabolismus $x patologie $7 D015470
650    _2
$a molekulární struktura $7 D015394
650    _2
$a inhibitory proteinkinas $x chemická syntéza $x chemie $x farmakologie $7 D047428
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a tyrosinkinasa 3 podobná fms $x antagonisté a inhibitory $x metabolismus $7 D051941
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a Research Support, U.S. Gov't, Non-P.H.S. $7 D013486
700    1_
$a Řezníčková, Eva $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic
700    1_
$a Hernandez, Delmis E $u Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States
700    1_
$a Peřina, Miroslav $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic
700    1_
$a Torregrosa-Allen, Sandra $u Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States
700    1_
$a Elzey, Bennett D $u Purdue University Center for Cancer Research, Purdue University, West Lafayette, Indiana 47907, United States $u Department of Comparative Pathobiology, Purdue University, West Lafayette, Indiana 47907, United States
700    1_
$a Škerlová, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic $u Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 14220, Czech Republic
700    1_
$a Ajani, Haresh $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic $1 https://orcid.org/0000000212233819
700    1_
$a Djukic, Stefan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic
700    1_
$a Vojáčková, Veronika $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic
700    1_
$a Lepšík, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic
700    1_
$a Řezáčová, Pavlína $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo Nám. 2, Prague 16610, Czech Republic $u Institute of Molecular Genetics of the Czech Academy of Sciences, Vídeňská 1083, Prague 14220, Czech Republic
700    1_
$a Kryštof, Vladimír $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic $1 https://orcid.org/0000000158382118 $7 xx0097406
700    1_
$a Jorda, Radek $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, Olomouc 78371, Czech Republic $1 https://orcid.org/0000000249057126
700    1_
$a Sintim, Herman O $u Department of Chemistry, Purdue University, West Lafayette, Indiana 47907, United States $u Institute for Drug Discovery, Purdue University, West Lafayette, Indiana 47907, United States
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 64, č. 15 (2021), s. 10981-10996
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34288692 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171825 $b ABA008
999    __
$a ok $b bmc $g 1925209 $s 1191186
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2021 $b 64 $c 15 $d 10981-10996 $e 20210721 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20230418

Find record

Citation metrics

Archiving options